Abstract
Although it is increasingly evident that cancer is influenced by signals emanating from tumor stroma, little is known regarding how changes in stromal gene expression affect epithelial tumor progression. We used laser capture microdissection to compare gene expression profiles of tumor stroma from 53 primary breast tumors and derived signatures strongly associated with clinical outcome. We present a new stroma-derived prognostic predictor (SDPP) that stratifies disease outcome independently of standard clinical prognostic factors and published expression-based predictors. The SDPP predicts outcome in several published whole tumor–derived expression data sets, identifies poor-outcome individuals from multiple clinical subtypes, including lymph node–negative tumors, and shows increased accuracy with respect to previously published predictors, especially for HER2-positive tumors. Prognostic power increases substantially when the predictor is combined with existing outcome predictors. Genes represented in the SDPP reveal the strong prognostic capacity of differential immune responses as well as angiogenic and hypoxic responses, highlighting the importance of stromal biology in tumor progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Kamangar, F., Dores, G.M. & Anderson, W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24, 2137–2150 (2006).
van 't Veer, L.J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
van de Vijver, M.J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
Perou, C.M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph-node–negative primary breast cancer. Lancet 365, 671–679 (2005).
Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869–10874 (2001).
Chi, J.T. et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3, e47 (2006).
Chang, H.Y. et al. Robustness, scalability and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 102, 3738–3743 (2005).
Glas, A.M. et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7, 278 (2006).
West, R.B. et al. Determination of stromal signatures in breast carcinoma. PLoS Biol. 3, e187 (2005).
Allinen, M. et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17–32 (2004).
Iyer, V.R. et al. The transcriptional program in the response of human fibroblasts to serum. Science 283, 83–87 (1999).
Singer, C.F. et al. Differential gene expression profile in breast cancer–derived stromal fibroblasts. Breast Cancer Res. Treat. published online, doi:10.1007/s10549-007-9725-2 (27 September 2007).
Buess, M. et al. Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol. 8, R191 (2007).
Bhowmick, N.A. & Moses, H.L. Tumor-stroma interactions. Curr. Opin. Genet. Dev. 15, 97–101 (2005).
Kim, J.B., Stein, R. & O'Hare, M.J. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol. 26, 173–185 (2005).
Tlsty, T.D. & Coussens, L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1, 119–150 (2006).
Finak, G. et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res. 8, R58 (2006).
Uzzan, B., Nicolas, P., Cucherat, M. & Perret, G.Y. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 64, 2941–2955 (2004).
Gruber, G. et al. Hypoxia-inducible factor 1 α in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res. 6, R191–R198 (2004).
Nikitenko, L.L., Fox, S.B., Kehoe, S., Rees, M.C. & Bicknell, R. Adrenomedullin and tumour angiogenesis. Br. J. Cancer 94, 1–7 (2006).
Bobrovnikova-Marjon, E.V., Marjon, P.L., Barbash, O., Vander Jagt, D.L. & Abcouwer, S.F. Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-κB and activating protein-1. Cancer Res. 64, 4858–4869 (2004).
Wang, D. et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J. Exp. Med. 203, 941–951 (2006).
Murdoch, C., Giannoudis, A. & Lewis, C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224–2234 (2004).
Bosco, M.C. et al. Hypoxia modifies the transcriptome of primary human monocytes: modulation of novel immune-related genes and identification of CC-chemokine ligand 20 as a new hypoxia-inducible gene. J. Immunol. 177, 1941–1955 (2006).
Yoshida, H., Broaddus, R., Cheng, W., Xie, S. & Naora, H. Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition. Cancer Res. 66, 889–897 (2006).
Lee, A.Y. et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 23, 6672–6676 (2004).
Dunn, G.P., Koebel, C.M. & Schreiber, R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836–848 (2006).
Ellyard, J.I., Simson, L. & Parish, C.R. TH2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 70, 1–11 (2007).
Mills, C.D., Kincaid, K., Alt, J.M., Heilman, M.J. & Hill, A.M. M-1/M-2 macrophages and the TH1/TH2 paradigm. J. Immunol. 164, 6166–6173 (2000).
Pearl, J. Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference. 116–226 (Morgan Kaufman Publishers, San Mateo, California, 1988).
Miller, L.D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects and patient survival. Proc. Natl. Acad. Sci. USA 102, 13550–13555 (2005).
Sotiriou, C. et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98, 262–272 (2006).
Nuyten, D.S. & van de Vijver, M.J. Gene expression signatures to predict the development of metastasis in breast cancer. Breast Dis. 26, 149–156 (2006).
Massague, J. Sorting out breast-cancer gene signatures. N. Engl. J. Med. 356, 294–297 (2007).
Pages, F. et al. Effector memory T cells, early metastasis and survival in colorectal cancer. N. Engl. J. Med. 353, 2654–2666 (2005).
Hiraoka, K. et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non–small-cell lung carcinoma. Br. J. Cancer 94, 275–280 (2006).
Dalberg, U., Markholst, H. & Hornum, L. Both Gimap5 and the diabetogenic BBDP allele of Gimap5 induce apoptosis in T cells. Int. Immunol. 19, 447–453 (2007).
Starnes, T. et al. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp. Hematol. 34, 1101–1105 (2006).
Boudreau, N. & Myers, C. Breast cancer–induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 5, 140–146 (2003).
Li, A., Dubey, S., Varney, M.L., Dave, B.J. & Singh, R.K. IL-8 directly enhanced endothelial cell survival, proliferation and matrix metalloproteinase production and regulated angiogenesis. J. Immunol. 170, 3369–3376 (2003).
Sica, A., Schioppa, T., Mantovani, A. & Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717–727 (2006).
Gupta, G.P. et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765–770 (2007).
Hofmann, H.S. et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non–small cell lung cancer patients. Clin. Cancer Res. 11, 1086–1092 (2005).
Lewis, C.E. & Pollard, J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605–612 (2006).
Teschendorff, A.E., Miremadi, A., Pinder, S.E., Ellis, I.O. & Caldas, C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 8, R157 (2007).
Fitzgibbons, P.L. et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124, 966–978 (2000).
Smyth, G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3 Article 3 (2004).
Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25–29 (2000).
Acknowledgements
We thank: D. Fleiszer, A. Loutfi, C. Milne, D. Owen, G. Pearl, R. Salasidis, F. Tremblay, M. Wexler (surgeons); F. Halwani, K. Khetani (pathologists); H. Barwick, A. Cuellar, D. Hori, S. Eng, L. Pasyuk, T. Vilhena, C. Palko-Condron (Pathology staff); C. Loiselle (Nursing); the MUHC Anaesthesia Department; A. Dedhar and A. Viquez (tissue and data collectors) for their assistance. We also thank C. Mihalcioiu, P. Siegel and members of the Park lab for their critical review of this manuscript. This work was supported by grants to M.P. from the Québec Breast Cancer Foundation, Genome Canada–Génome Québec, Valorisation-Recherche Québec and Fonds de la Récherche en Santé du Québec and a Canadian Institutes of Health Research (CIHR) Team Grant; a National Science and Engineering Research Council of Canada Discovery Grants Program grant to M.H.; a CIHR McGill University Cancer Consortium Training Award to G.F.; a US Department of Defense Breast Cancer Predoctoral Traineeship Award to F.P.; MUHC Research Institute and MUHC Department of Medicine Fellowships to N.B.; and Cedars Cancer Institute Fellowships to S.S. and N.B. M.P. holds the Diane and Sal Guerrera Chair in Cancer Genetics at McGill University.
Author information
Authors and Affiliations
Contributions
G.F. designed and implemented the data analysis pipeline for the data generated for this study, developed methods and software for data analysis, analyzed and interpreted the data, and contributed to manuscript preparation. N.B. coordinated experiments, supervised the quantitative RT-PCR and immunohistochemical validation aspects of this study, participated in discussions of data analysis and interpretation, and contributed to manuscript preparation. F.P. contributed to methods and software development and participated in discussions of data analysis and interpretation. S.S. developed protocols for tissue storage, LCM, linear amplification and labeling, and supervised these applications. M.S. performed LCM and immunohistochemistry. H.Z. performed quantitative RT-PCR and isolated RNA after LCM. H.C. prepared samples and conducted gene expression profiling. G.O. performed pathological and histological analysis of samples and gave advice regarding immunohistochemistry. S.M. contributed to clinical analyses and tissue procurement. A.O. performed pathological and histological analyses on tissue samples before LCM. M.H. supervised the bioinformatics and biostatistics aspects of the project, designed and coordinated analyses, and contributed to manuscript preparation. M.P. initiated and supervised the tissue collection and microarray preparation, supervised the expression profiling aspect of this project, designed and coordinated experiments and contributed to manuscript preparation.
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–4, Supplementary Tables 1 and 2, Supplementary Results and Supplementary Methods (PDF 1644 kb)
Rights and permissions
About this article
Cite this article
Finak, G., Bertos, N., Pepin, F. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14, 518–527 (2008). https://doi.org/10.1038/nm1764
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1764
This article is cited by
-
ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis
Breast Cancer Research (2024)
-
High expression of IL4I1 is correlated with poor prognosis and immune infiltration in thyroid cancer
BMC Endocrine Disorders (2023)
-
Patient-derived scaffolds representing breast cancer microenvironments influence chemotherapy responses in adapted cancer cells consistent with clinical features
Journal of Translational Medicine (2023)
-
Pubertal exposure to dietary advanced glycation end products disrupts ductal morphogenesis and induces atypical hyperplasia in the mammary gland
Breast Cancer Research (2023)
-
A high-throughput test enables specific detection of hepatocellular carcinoma
Nature Communications (2023)